Five Questions That Determine The Success Of Your PROTAC Programs

By Sachin Mangale, Product Marketing Lead – Discovery Services, Syngene International Ltd.

Proteolysis-targeting chimeras (PROTACs) and other protein degradation strategies are gaining increasing prominence due to the benefits they offer over small molecules in drug discovery for challenging targets. These include the ability of PROTAC molecules to selectively target proteins for degradation, their potential for sustained action, and low dosages required for degradation.

This blog article reviews five questions that need to be addressed when launching a PROTAC development program.